SCHEMBL4774191

SCHEMBL4774191

N#Cc1cnc2cnc(F)cc2c1Nc1ccc(F)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 8/20 0.55
ERBB2 P04626 5/20 0.55
MAP3K8 P41279 12/20 0.54
SRC P12931 2/20 0.51
MAPK13 O15264 2/20 0.51
MAPK12 P53778 2/20 0.51
MAPK11 Q15759 2/20 0.51
MAPK14 Q16539 2/20 0.51
EIF2AK2 P19525 1/20 0.51
PRKD3 O94806 1/20 0.49
PRKCG P05129 1/20 0.49
PRKCB P05771 1/20 0.49
PRKCA P17252 1/20 0.49
PRKCH P24723 1/20 0.49
PRKCI P41743 1/20 0.49
PRKCE Q02156 1/20 0.49
MAP2K1 Q02750 1/20 0.49
PRKCQ Q04759 1/20 0.49
PRKCZ Q05513 1/20 0.49
PRKCD Q05655 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774213 0.89 EGFR (0.58) EGFRERBB2MAP3K8SRCMAPK13
SCHEMBL4766964 0.89 EGFR (0.70) EGFRERBB2MAP3K8SRCMAPK13
SCHEMBL4775921 0.88 SRC (0.64) EGFRERBB2MAP3K8SRCMAPK13
SCHEMBL4776688 0.87 EGFR (0.67) EGFRERBB2MAP3K8SRCMAP2K1
SCHEMBL4772668 0.85 SRC (0.65) EGFRERBB2MAP3K8SRCMAPK13
SCHEMBL4766938 0.85 MAP2K1 (0.64) EGFRERBB2MAP3K8MAP2K1
SCHEMBL4775832 0.85 EGFR (0.64) EGFRERBB2MAP3K8SRCMAP2K1
SCHEMBL4775833 0.85 MAP2K1 (0.60) EGFRERBB2MAP3K8MAP2K1
SCHEMBL4767089 0.84 EGFR (0.66) EGFRERBB2MAP3K8SRCMAPK13
SCHEMBL5125249 0.84 EGFR (0.69) EGFRERBB2MAP3K8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432279-B2 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2008-10-07 US disclosed
CN-101223170-A 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of TPL2 kinase and methods of making and using the same WYETH CORP (US) 2008-07-16 CN disclosed
EP-1881981-A1 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-01-30 EP disclosed
US-20060276498-A1 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-12-07 US disclosed
WO-2006124944-A1 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276498-A1 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CNKSR1, DTYMK EGFR 2871/4885ERBB2 1101/4885MAP3K8 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.